Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 50.52% | 475.34% | 90.78% | 23.02% | 101.39% |
| Total Depreciation and Amortization | 20.71% | 0.69% | 15.47% | 15.53% | 25.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -64.66% | -31.05% | -52.92% | 560.47% | -169.71% |
| Change in Net Operating Assets | -65.21% | 12,428.57% | -61.74% | -92.11% | 29.89% |
| Cash from Operations | 30.34% | 138.04% | 110.54% | 42.85% | 893.17% |
| Capital Expenditure | -70.21% | -54.56% | -38.56% | -53.05% | -39.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -37,100.00% | -- | -- | -- | 99.97% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.10% | 86.98% | -425.95% | -863.30% | 47.55% |
| Cash from Investing | -45.87% | 25.52% | 16.55% | -184.67% | 34.31% |
| Total Debt Issued | -100.00% | 35.08% | -- | 0.13% | -100.00% |
| Total Debt Repaid | -100.01% | -32.44% | -69.86% | 64.48% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 26.59% | -58.73% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.21% | -14.93% | -14.89% | -15.15% | -14.71% |
| Other Financing Activities | 45.32% | 36.15% | -280.00% | -76.06% | -45.25% |
| Cash from Financing | -1,176.63% | 151.30% | -180.03% | 543.21% | -106.36% |
| Foreign Exchange rate Adjustments | 84.35% | -86.03% | 562.25% | 471.55% | -431.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,388.66% | 4,312.65% | -62.98% | 51.14% | -123.16% |